Tango Therapeutics, Inc. (TNGX)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 53.8M | 0.00 | 0.00 | 0.00 |
| Operating Income | 14.1M | (41.9M) | (48.8M) | (59.8M) |
| Net Income | 15.9M | (38.7M) | (45.5M) | (55.3M) |
| Diluted EPS | $0.13 | $-0.29 | $-0.32 | $-0.37 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 24.9M | 36.5M | 42.1M | 62.4M |
| Operating Income | (111.1M) | (114.2M) | (145.6M) | (111.3M) |
| Net Income | (108.2M) | (101.7M) | (130.3M) | (101.6M) |
| Diluted EPS | $-1.23 | $-1.08 | $-1.19 | N/A |